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Background: To repair fractures with large bone defects or gaps, demineralized allogenic bone matrix (DBM) is
often applied to the fracture site. However, studies have shown that the use of DBM alone has limited efficacy for
repairing fractures. In the present study, we developed an allogenic demineralized bone powder (DBP) with basic
fibroblast-derived growth factor containing a polycystic kidney disease (PKD) domain and collagen-binding domain
(CBD) from Clostridium histolyticum collagenase (ColH) and investigated the stimulatory effects of bFGF-PKD-CBD
combined with allogenic DBP on bone growth in a mouse femur fracture model.
Methods: DBP mixed with either phosphate-buffered saline (PBS) (DBP/PBS), 0.58 nmol basic fibroblast growth
factor (bFGF) (0.58 nmol DBP/bFGF), 0.058 nmol bFGF-PKD-CBD (0.058 nmol DBP/bFGF-PKD-CBD), or 0.58 nmol
bFGF-PKD-CBD (0.58 nmol DBP/bFGF-PKD-CBD) was grafted into fracture sites.
Results: bFGF-PKD-CBD/DBP composite accelerates callus formation in a bone fracture model in mice and clearly
showed that the composite also increases bone mineral density at fracture sites compared to bFGF/DBP. In
addition, bFGF-PKD-CBD/DBP increased callus volume and bone mineral content to similar levels in fractures treated
with a tenfold higher amount of bFGF at 4 weeks.
Conclusions: Our results suggest that bFGF-PKD-CBD/DBP may be useful for promoting fracture healing in the
clinical setting.
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Allogenic demineralized bone matrixBackground
Certain types of fractures are associated with delayed
union or nonunion and therefore require bone grafting
[1-3]. Allogenic demineralized bone matrix (DBM) is a
useful bone-filling material because it serves as biologic
osteoconductive scaffold that retains the trabecular col-
lagenous structure of the original tissue, and has bone* Correspondence: kuchida@med.kitasato-u.ac.jp
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unless otherwise stated.morphogenetic protein 2 (BMP-2) retention/liberation
properties [4,5]. Due to these properties, DBM is one of
the most extensively used bone scaffolds in the clinical
setting worldwide [1,6]. However, studies have shown
that the use of DBM alone has limited efficacy for re-
pairing bone defects [7,8].
To overcome this limitation, strategies for the repair
of large fractures with DBM should include bone-
inducing growth factors. A number of growth factors,
such as BMP-2, basic fibroblast growth factor (bFGF),
and osteogenic protein-1 (OP-1), have been studied forhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[9-14]. For example, BMP-2 and bFGF have been shown
to accelerate the healing of fractures and bone defects
[11,12], and OP-1 has been successfully used to treat tibial
nonunions [9,10]. However, in practice, bone-inducing
factors rapidly diffuse in body fluid and fall below thera-
peutic concentrations at defect sites. For this reason, large
doses and/or repeated administrations of growth factors
are required for sustained therapeutic effect, but such dos-
ing regimens may be clinically impractical and expensive
and can lead to adverse side effects [15,16]. To increase
the osteogenic potential of bone-inducing growth factors,
they should ideally be combined with a carrier, such as col-
lagen or DBM, to promote their retention at fracture sites.
We previously fused the collagen-binding domain
(CBD) and polycystic kidney disease (PKD) domain of
Clostridium histolyticum class II collagenase (ColH) to
bFGF and showed that the subcutaneous injection of this
collagen-binding bFGF fusion protein (bFGF-PKD-CBD)
without carrier into nude mice had more potent skin
fibroblast growth-promoting effects at the injection site
than native bFGF [17]. bFGF-PKD-CBD also markedly
enhanced bone formation when loaded onto autologous
DBM that was grafted onto intact rat femurs [18]. Based
on these findings, we speculated that the combination of
bFGF-PKD-CBD and DBM may promote the retention
of bFGF at injury sites and thereby accelerate bone
repair. However, the efficacy of this treatment approach
has only been evaluated with autologous DBM and
healthy bone, and the bone formation-promoting effects
of bFGF-PKD-CBD in combination with allogenic DBM
in bone injury models have not been determined.
Here, we investigated the stimulatory effects of bFGF-
PKD-CBD combined with allogenic demineralized bone
powder (DBP) on bone growth in a mouse femur fracture
model.
Methods
Preparation of allogenic dematerialized bone powder
Both femurs were harvested from 36 C3H/HeN (H-2k)
mice, and bone lipids were removed by treatment
with chloroform/methanol. The harvested femoral bones
were broken into small fragments, which were then passed
through a 1-mm filter to collect the bone powder. To pre-
pare DBP, the bone powder was demineralized using 0.6
N HCl for 18 h at 4°C. The particle size distributions were
determined by laser scattering using a LMS-30 Micron
Sizer (Seishin Enterprise Co., Ltd., Tokyo, Japan) and cu-
mulative size distribution limits of D10, D50, and D90,
which correspond to the percentage of particles (10%,
50%, and 90%, respectively) in a sample that is below a
certain size. The surfaces of the DBP were observed by
scanning transmission electron microscopy (SEM; JSM-
7400F; JEOL Ltd., Tokyo, Japan).Preparation of bFGF and bFGF-PKD-CBD
Recombinant human bFGF was purchased from Kaken
Pharmaceuticals (Tokyo, Japan). The construction of the
fusion protein of bFGF, PKD, and the CBD derived from
C. histolyticum class II collagenase (ColH) was previously
described [18]. The biological activities of purified bFGF-
PKD-CBD were confirmed using a proliferation assay with
cultured periosteal mesenchymal cells [19]. bFGF-PKD-
CBD exhibited the same cell proliferation ability as bFGF
in vitro. The affinity of bFGF-PKD-CBD for allogenic DBP
was confirmed in vitro by ELISA, as previously described
[18]. In the assay, 0.064 nmol of bFGF-PKD-CBD bound
to 1 mg of allogenic DBP.
Fracture generation
All procedures involving the handling of animals ad-
hered to the guidelines of the animal ethics committee
of Kitasato University. A specific pathogen-free colony
of C57BL/6J mice was housed in a semi-barrier system
under controlled conditions (temperature, 23°C ± 2°C;
humidity, 55% ± 10%; and lighting, 12-h light/dark cycle)
throughout the study at Nippon Charles River Laborator-
ies (Kanagawa, Japan). Mice were allowed access to stand-
ard rodent chow (CRF-1; Oriental Yeast Co., Ltd., Tokyo,
Japan) and water ad libitum. Fractures were generated in
the femurs of 72 C57BL/6J mice by first making a 4-mm
medial parapatellar incision in the left knee under sterile
conditions to laterally dislocate the patella [20]. A 0.5-mm
hole was then drilled into the intracondylar notch, into
which a nail (0.5 mm in diameter) was inserted retrograde
for the creation of fractures, which were generated with a
wire saw (0.22 mm in diameter) using a small lateral ap-
proach. After performing the fracture generation proced-
ure, the nail was implanted deeply to stabilize the fracture.
Soft x-rays were used to confirm the successful creation of
fractures [20]. As we previously demonstrated that the
combination of 0.58 nmol bFGF-PKD-CBD and collagen
powder accelerated bone formation in mice [19], in the
present study, the C57BL/6J mice were divided into four
groups (18 mice/group), 8 mg DBP mixed with either
phosphate-buffered saline (PBS) (DBP/PBS, control
group), 0.58 nmol bFGF (0.58 nmol DBP/bFGF group),
0.058 nmol bFGF-PKD-CBD (0.058 nmol DBP/bFGF-
PKD-CBD group), or 0.58 nmol bFGF-PKD-CBD (0.58
nmol DBP/bFGF-PKD-CBD group) was grafted into frac-
ture sites. The mice were allowed to use their fractured
leg without restriction immediately after the grafting
procedure until micro-CT analysis was performed at 2, 4,
and 6 weeks (n = 6, each time point).
Quantification of the mineral content and volume of
newly formed callus
Femurs and the surrounding muscle were excised from
sacrificed mice at 2, 4, and 6 weeks after fracture
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paraformaldehyde for 48 h at 4°C. Micro-CT images of
whole femurs in PBS were obtained using a microfocus
X-ray CT system (inspeXio SMX-90CT; Shimadzu Co.,
Ltd., Tokyo, Japan) and the following settings: acceler-
ation voltage, 90 kV; current, 110 mA; voxel size, 20
μm/pixel; and matrix size, 1,024 × 1,024. From the
obtained images, 10-mm regions of interest (500 slices)
in the midfemur were defined. Three-dimensional (3D)
image analysis software (Tri-3D-Bon; Ratoc System
Engineering Co., Ltd, Tokyo, Japan) was used to meas-
ure new bone volume and bone mineral content in the
defined regions, as previously described [21]. For asses-
sing new bone volume and bone mineral content, a hy-
droxyapatite (HA) calibration curve was generated from
the data obtained from phantom images prepared with
200, 300, 400, 500, 600, 700, and 800 mg HA/cm3. The
bone mineral content in each sample was determined by
comparing the measured densities in the micro-CT im-
ages to the HA calibration curve, and new bone was de-
fined using a threshold value of ≥300 mg/cm3.
Statistical analysis
Differences among the PBS, bFGF, and bFGF-PKD-CBD
treatment groups were examined using one-way ANOVA
with the Fisher’s least significant difference test. All sta-
tistical analyses were performed using SPSS softwareFigure 1 Appearance and SEM images of prepared demineralized allogeni
1.5-cm diameter tube. (B) SEM image of the prepared bone powder. Scale
prepared demineralized allogenic bone powder particles.(Version 11.0; SPSS, Inc., Chicago, IL, USA). A P value of
<0.05 was considered statistically significant.
Results
Characterization of allogenic DBP
The prepared allogenic DBP was morphologically char-
acterized by SEM, which showed that the particles
appeared irregular in shape and had a rough surface
(Figure 1A, B). Based on measurements of the diameter
of the bone particles, the values for D10, D50, and D90
were determined to be 154.32, 266.11, and 439.94 μm,
respectively (Figure 1C).
Effect of bFGF-PKD-CBD-loaded DBP on callus formation
Callus formation at fracture sites in mice femurs grafted
with DBP in PBS (PBS/DBP) or DBP loaded with bFGF
(bFGF/DBP) or bFGF-PKD-CBD (0.058 nmol and 0.58
nmol bFGF-PKD-CBD/DBP) was evaluated after 2, 4,
and 6 weeks by micro-CT imaging (Figure 2A–F). Simi-
lar amounts of callus formation and bone mineral con-
tent were observed for femurs treated with PBS/DBP,
bFGF/DBP, 0.058 nmol bFGF-PKD-CBD/DBP, and 0.58
nmol bFGF-PKD-CBD/DBP at 2 weeks (Figure 2E, F).
However, after 4 weeks, fracture sites grafted with 0.58
nmol bFGF/DBP and 0.058 or 0.58 nmol bFGF-PKD-
CBD/DBP had significantly higher levels of callus volume
and bone mineral content compared to those grafted withc bone powder. (A) Photograph of the prepared bone powder in a
bar indicates 100 μm. (C) Graph showing the size distribution of the
Figure 2 3D micro-CT analysis of femurs after grafting of demineralized allogenic bone powder loaded with bFGF-PKD-CBD. 3D micro-CT images
of fractured mouse femurs treated with (A) PBS/DBP, (B) 0.58 nmol bFGF/DBP, (C) 0.058 nmol bFGF-PKD-CBD/DBP, and (D) 0.58 nmol bFGF-PKD-CBD/
DBP at 6 weeks. Green: newly formed bone; gray: existing bone. The scale bars indicate 3 mm. (E) Callus area and (F) bone mineral content at fracture
sites for the indicated treatment groups. Data are presented as the mean ± standard error (S.E.; error bars; n = 6). a: P < 0.05 compared with the control
group (PBS/DBP). b: P < 0.05 compared with the 0.58 nmol bFGF group.
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and bone mineral content in fracture sites grafted with
0.58 nmol bFGF-PKD-CBD/DBP were significantly higher
than those found in the other three groups of treated
femurs. In addition, no differences in callus formation or
bone mineral content in fracture sites treated with PBS/
DBP, bFGF/DBP, or 0.058 nmol bFGF-PKD-CBD/DBP
femur were observed at 6 weeks (Figure 2E, F).
Discussion
In mice, femur fracture sites grafted with 0.58 nmol
bFGF-PKD-CBD/DBP had significantly higher levels of
callus volume and bone mineral content at 4 weeks com-
pared to fractures treated with DBP alone. In addition,
treatment with a lower concentration of bFGF-PKD-CBD/
DBP than that used for bFGF/DBP led to higher compara-
tive callus volume and bone mineral content compared to
fractures treated with DBP alone at 4 weeks. Notably, the
callus volume and bone mineral content in fracture sites
grafted with 0.58 nmol bFGF-PKD-CBD/DBP at 6 weeks
were higher than those of the other three treatment
groups. Taken together, these results suggest that bFGF-
PKD-CBD/DBP may be useful for promoting fracture
healing in the clinical setting.
Demineralized bone material is a useful bone-filling
material due to its excellent BMP-2 retention/liberation
properties, which promotes cell-mediated mineralized
matrix deposition [22,23]. However, implanting DBMalone for the reconstruction of bone defects often fails
to achieve repair [7]. To overcome this limitation,
Aspenberg et al. [24] mixed allograft bone with bFGF
and showed that this combination increased the calcium
content of bone after implantation into defect sites in
rats. Lu and Rabie [25] also demonstrated that the com-
bination of allograft bone and bFGF accelerates bone
formation in rabbit. We previously established a method
for accelerating periosteal bone formation using autolo-
gous DBP decorated with collagen-binding bFGF protein
fused with a PKD domain and CBD derived from C.
histolyticum class II collagenase (ColH). In the present
study, we demonstrated that the bFGF-PKD-CBD/DBP
composite accelerates callus formation in a bone fracture
model in mice and clearly showed that the composite also
significantly increases the bone mineral density at fracture
sites compared to bFGF/DBP. Notably, the callus volume
and bone mineral content of fracture sites in the 0.58
nmol bFGF/DBP and 0.058 nmol bFGF-PKD-CBD/DBP
treatment groups had decreased at 6 weeks compared to 4
weeks. This decrease was attributable to bone remodeling,
which occurred when bone formation reached a plateau
during the fracture healing process at approximately
4 weeks in these two treatment groups. In contrast,
the callus volume and bone mineral content of femurs
in the 0.58 nmol bFGF-PKD-CBD/DBP group increased
throughout the 6-week recovery period, suggesting
that the bFGF-PKD-CBD/DBP composite continuously
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at fracture sites due to the presence of the PKD and CBD.
In addition, bFGF-PKD-CBD/DBP increased callus
volume and bone mineral content to similar levels in
fractures treated with a tenfold higher amount of bFGF
at 4 weeks. Taken together, these findings suggest that
bFGF-PKD-CBD/DBP composite has greater fracture
healing effects than bFGF alone, even at markedly lower
concentrations. This property may therefore reduce the
adverse effects of bFGF, such as thrombocytopenia, renal
toxicity, and malignant cell activation [15,16], when used
in the clinical setting.
During fracture healing, periosteal mesenchymal cells
proliferate in the early phase and then differentiate into
osteoblasts, which undergo expansion in the late phases
and are involved in the synthesis of new bone. In the
osteoinductive process, bFGF and BMP-2 play important
roles in periosteal proliferation and osteogenic differen-
tiation, respectively [26]. The osteogenic-promoting ef-
fects of synthetic bFGF and BMP-2 have also been
reported [27-29]. For example, Akita et al. [27] showed
that coadministration of BMP-2 and bFGF accelerates
cranial bone defect healing. The combined delivery of
BMP-2 and bFGF in the form of nanostructured col-
loidal gelatin gel also promotes bone regeneration in a
rat femoral condyle defect model [28]. These findings
suggest that the allogenic DBM/bFGF-PKD-CBD com-
posite may stimulate both periosteal mesenchymal cell
proliferation in the early phase of fracture healing due
to the bFGF component and osteogenic differentiation
in late phases due to the BMP-2 properties of DBM,
leading to efficient fracture repair. Thus, allogenic DBM/
bFGF-PKD-CBD is a promising composite material for
accelerating bone formation during fracture healing in the
clinical setting.
Conclusions
We revealed that the anchoring of bFGF to demineralize
allogenic DBP using the PKD and CBD derived from C.
histolyticum collagenase effectively promotes fracture
healing when this composite is applied to fracture sites.
Specifically, the combination of DBP and the bFGF-
PKD-CBD fusion protein increased callus volume and
bone mineral content when grafted onto fractured mice
femurs. bFGF-PKD-CBD/DBP composite is therefore a
promising agent for promoting fracture healing in the
clinical setting.
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